Each uncoated tablet contains Nevirapine 200 mg
Nevirapine Oral Suspension
Each 5 ml contains Nevirapine 50 mg / 5 ml
Nevirapine is prescribed for use in combination with other antiretroviral agents for the treatment of HIV-1 infection.
The recommended dose for nevirapine is one 200 mg tablet daily for the first 14 days (this lead-in period should be prescribed because it has been found to lessen the frequency of rash), followed by one 200 mg tablet twice daily, in combination with antiretroviral agents.
2 months - 8 years : 4mg/kg once daily for the first 14 days followed by 7 mg/ kg once daily thereafter.
8 years and older : 4mg/kg once daily for two weeks followed by 4mg/kg twice daily thereafter.
The total daily dose should not exceed 400mg for any patient.
Monitoring of patients
Clinical chemistry tests, which include liver function tests, should be performed prior to initiating nevirapine therapy and at appropriate intervals during therapy.
Nevirapine should be discontinued if patients experience severe rash or a rash accompanied by constitutional findings.
Patients experiencing rash during the 14-day lead-in period of 200 mg/day should not have their nevirapine dose increased until the rash has resolved.
Nevirapine administration should be interrupted in patients experiencing moderate or severe liver function test abnormalities (excluding GGT), until the liver function test elevations have returned to baseline.
Nevirapine may then be restarted at 200 mg per day.
Increasing the daily dose to 200 mg twice daily should be done with caution, after extended observation.
Nevirapine should be permanently discontinued if moderate or severe liver function test abnormalities recur.
Patients who interrupt nevirapine dosing for more than 7 days should restart the recommended dosing, using one 200 mg tablet daily for the first 14 days (lead-in) followed by one 200 mg tablet twice daily.
IMPAIRED RENAL AND HEPATIC FUNCTION
No data are available to recommend a dosage of nevirapine in patients with hepatic dysfunction, renal insufficiency, or undergoing dialysis.
Nevirapine is contraindicated in patients with clinically significant hypersensitivity to any of the components contained in the tablet or the oral suspension.
- Strip of 10 tablets;
- Container of 60 tablets;
- Bottle of 100 ml with syringe;